# Table of Contents

## Section I: General Information

<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Introduction to International Regulatory Affairs</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Updated by Rowena Cook, MS, RAC and Sharad Mi Shukla, RAC</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Crisis Management for the Healthcare Product Industry</td>
<td>11</td>
</tr>
<tr>
<td></td>
<td>Updated by Treena Jackson, MS, MA, CQA, RAC (US), CSSGB</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Clinical Trials, Good Clinical Practice, Regulations, and Compliance</td>
<td>19</td>
</tr>
<tr>
<td></td>
<td>Updated by Anu Gaur, PhD, MBA, MSRA, RAC, Bettina Merz-Nideroest, MPharm, and Andrea Zobel, PhD</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>In-Country Representation</td>
<td>35</td>
</tr>
<tr>
<td></td>
<td>Updated by Pei-Ting S. Chou, PCQI, RAC</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>International Advertising and Promotion</td>
<td>55</td>
</tr>
<tr>
<td></td>
<td>Updated by Treena Jackson, MS, MA, CQA, RAC (US), CSSGB</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>Compliance and Enforcement</td>
<td>65</td>
</tr>
<tr>
<td></td>
<td>Updated by David W. Husman, PhD, ASQ CPGP, RAC and John Rossman, MBEE, RAC</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>International Counterfeit Regulations</td>
<td>87</td>
</tr>
<tr>
<td></td>
<td>Updated by Jos Kraus, PharmD, FRAPS and Siegfried Schmitt, PhD</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>Regulatory Reliance</td>
<td>113</td>
</tr>
<tr>
<td></td>
<td>By Daniela Drago, PhD, RAC and Murray M. Lumpkin, MD, MSc</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>Pricing and Reimbursement</td>
<td>123</td>
</tr>
<tr>
<td></td>
<td>Updated by Anu Gaur, PhD, MBA, MSRA, RAC</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>Health Technology Assessment (HTA)</td>
<td>143</td>
</tr>
<tr>
<td></td>
<td>Updated by Azzurra Ravizza, MSc and Monique Carter, MS, RAC</td>
<td></td>
</tr>
</tbody>
</table>

## Figures

<table>
<thead>
<tr>
<th>Figure</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>3-1</td>
<td>Acceptance of Foreign Clinical Data</td>
<td>25</td>
</tr>
<tr>
<td>3-2</td>
<td>Quality Management System</td>
<td>30</td>
</tr>
<tr>
<td>6-1</td>
<td>TPLC Cycle for Devices</td>
<td>67</td>
</tr>
<tr>
<td>6-2</td>
<td>Medical Device Design Control and Review Process</td>
<td>71</td>
</tr>
<tr>
<td>7-1</td>
<td>WHO Global Monitoring System</td>
<td>106</td>
</tr>
<tr>
<td>8-1</td>
<td>Building Confidence and Trust for Greater Reliance</td>
<td>115</td>
</tr>
</tbody>
</table>
Section II: Pharmaceuticals

Chapter 11: Premarket Requirements/Dossier Requirements

Chapter 12: Authorization Procedures for Pharmaceutical Products
Chapter 13: Stability Test Requirements ........................................................... 207
*Updated by Sharry Arora, MPharm and Rosie Dawes*

Chapter 14: Quality Systems and Inspectorate Process for Pharmaceuticals .............................................................. 221
*Updated by Siegfried Schmitt, PhD*

Chapter 15: Generic Drug Products .............................................................................. 243
*Updated by Pallavi Trivedi, MPH, RAC and Anu Gaur, PhD, MBA, MSRA, RAC*

Chapter 16: Over-the-Counter (OTC) Products ........................................................................... 261
*Updated by Robert Falcone, PhD*

Chapter 17: Pharmaceutical Postmarketing and Compliance .............................................. 273
*Updated by Kathrin Schalper, PhD, RAC*

**Figures**

Figure 11-1. CTD Organization ................................................................................ 180
Figure 14-1. Drug Lifecycle Regulations .................................................................... 222
Figure 14-2. Assessors and Inspectors ...................................................................... 223
Figure 14-3. EU Legal Instruments ............................................................................. 226
Figure 14-4. Inspections as Part of the Drug Approval Process ................................. 227
Figure 17-1. MedDRA Coding Hierarchy .................................................................... 282

**Tables**

Table 11-1. ACTD Format and Content ....................................................................... 184
Table 12-1. ICH Members (as of May 2020) ............................................................... 188
Table 12-2. Country-Specific Regulatory Requirements .............................................. 190
Table 13-1. Climatic Zones ....................................................................................... 208
Table 13-2. WHO Recommended Stability Testing Conditions for Drug Substance and Drug Product .... 212
Table 13-3. Recommended Stability Storage Conditions for Refrigerated and Frozen Drug Substance and Drug Product ...................................................... 213
Table 13-4. Country-Specific Climatic Zones and Stability Data Requirements for Asia Pacific Region .... 216
Table 13-5. Country-Specific Climatic Zones and Stability Data Requirements for Latin America ......................................................................................... 217
Table 13-6. Country-Specific Climatic Zones and Stability Data Requirements for SEE, Middle East, and Africa .............................................................................. 218
Table 14-1. PIC/S Member States ............................................................................... 235
Table 15-1. Comparative Study Parameter Assessment Between the US, EU, and Canada .... 245
Table 15-2. GDUFA II User Fee Rates ........................................................................ 248
Table 15-3. Comparison of Generic Product Development Regulatory Requirements in Select Countries 249
Table 17-1. MAH Reporting Requirements .................................................................. 283

**Section III: Medical Devices**

Chapter 18: Medical Device Premarket Requirements ...................................................... 289
*Updated by Gert Bos, MSc, PhD, FRAPS*
Section IV: Biologics

Chapter 25: High-Risk Products: Products Derived from Biotechnology .......................................................... 391
Updated by Jocelyn Jennings, MS, RAC and Angela L. Nelson, MBA, RAC

Chapter 26: Biosimilars: Basics and Recent Developments ........................................................................ 411
Updated by Pallavi Trivedi, MPH, RAC

Chapter 27: Vaccines ........................................................................................................................................... 457
Updated by Nicole Beard, MSc, PhD

Figures
Figure 26-1. Influence of Stakeholders as Drives of Biosimilars ........................................................................ 415
Figure 26-2. Standalone vs. Abbreviated Development Programs ................................................................. 432
Figure 26-3. Regulation in Latin America ........................................................................................................... 451
Figure 27-1. OCABR Decision Flowchart (Extracted from EU Administrative Procedure for Official Control Authority Batch Release—Human Vaccine and Blood Derived Medicinal Products) ............................................. 467
Figure 27-2. Process of Influenza Vaccine Virus Selection and Development .................................................. 469
Figure 27-3. Standard Evaluation Process Compared With Rolling Review of COVID-19 Vaccines .............. 471

Tables
Table 26-1. Terminology Used in Regulatory Guidelines .............................................................................. 413
Table 26-2. WHO Written Procedures Providing Guidance on Evaluation of SBPs ........................................ 416
Table 26-3. Advantages and Disadvantages of Equivalence/Noninferiority Designs for SBPs ......................... 417
Table 26-4. EMA Biosimilar Marketing Approvals via the Centralised Procedure ........................................ 419
Table 26-5. Biosimilars Recommended for Granting Upon Positive Opinion Adopted by CHM ..................... 424
Table 26-6. EU Guidelines for Biosimilars .......................................................................................................... 425
Table 26-7. Typical Biosimilar Product Marketing Application Dossiers and Data Requirement for Approval in the EU .......................................................................................................................... 427
Table 26-8. Types of Formal FDA Meetings for Biosimilar Applications .......................................................... 431
Table 26-9. Typical Dossier and Data Requirements for US Biosimilar Applications ..................................... 434
Table 26-10. PMDA-Approved Biosimilars as of November 2020 ................................................................. 438
Table 26-11. Typical Dossier and Data Requirements for Biosimilar Applications in Japan .......................... 440
Table 26-12. Typical Application Dossier and Data Requirements for Biosimilar Marketing Applications ...... 441
Section V: Other Product Classifications

Chapter 28: Products Manufactured from Human Blood and Plasma ................................................................. 477

Updated by Indraneel Dasari, RAC

Chapter 29: Principles of Rare Diseases and Orphan Products Development .......................................................... 507

Updated by Todd J. Banks, PharmD, RPh, Ken Bonnell, MS, MBA, and Phu Bo Chung, JD, MS, RAC

Chapter 30: Combination Products ..................................................................................................................... 523

Updated by Deanna Hughes, MS, RAC and Beat U. Steffen, MSc, MBA

Chapter 31: Regulatory Considerations for Cell-Based Medicinal Products ........................................................ 541

By Indraneel Dasari, RAC

Chapter 32: Food Supplements and Food for Special Medical Purposes ............................................................ 561

Updated by Manfred Ruthsatz, PhD, RAC, FRAPS

Chapter 33: Botanical Drug Products and Traditional Medicine ............................................................................ 575

Updated by Robert Falcone, PhD

Chapter 34: Global Pediatric Drug Development ................................................................................................. 597

By Lynne Georgopoulos, RN, MSHS, RAC and Azzurra Ravizza, MSc

Chapter 35: Cosmetic Products ........................................................................................................................... 629

By Nicole Beard, MSc, PhD

Chapter 36: Veterinary Medicinal Products ........................................................................................................ 639

Updated by Theo Kanellos, DVM, MSc, PhD

Figures

Figure 28-1. Convalescent Plasma Collection Workflow ...................................................................................... 483

Figure 28-2. Overview of Blood Product Manufacturing Process ......................................................................... 484

Figure 28-3. Approaches to be Employed During Blood Product Processing .................................................... 489

Figure 31-1. Cell Therapy Product Sources and ATMP Manufacturing Process Overview ................................. 543

Figure 31-2. Indications of Advanced Therapy Trials ......................................................................................... 544

Figure 31-3: Summary Schematic of DC Monocyte-Based Therapy for COVID-19 Treatment .......................... 547
Appendices

Regulations Across Chapters—Comparative Matrix ................................................................. 657
Abbreviations and Acronyms .................................................................................................. 693
Glossary of Terms .................................................................................................................. 705
Index ....................................................................................................................................... 713